Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
Crossref DOI link: https://doi.org/10.1007/s00280-022-04421-7
Published Online: 2022-03-18
Published Print: 2022-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hibma, Jennifer E. http://orcid.org/0000-0002-6547-2186
O’Gorman, Melissa
Nepal, Sunil
Pawlak, Sylvester
Ginman, Katherine
Pithavala, Yazdi K.
Text and Data Mining valid from 2022-03-18
Version of Record valid from 2022-03-18
Article History
First Online: 18 March 2022